
What artificial food dye bans mean for your health and fridge
Growing concerns about the
health effects of food dyes
have led to a
new West Virginia law
banning seven artificial food dyes – but what does this mean for those in other states? And where else are bans in place?
Dr. Céline Gounder, CBS News medical contributor and editor-at-large for public health at KFF Health News, told "CBS Mornings Plus" Wednesday that the impact of West Virginia's move is yet to be seen.
"If this had been California or New York or Texas, that is a different thing, because then you're really having such a big impact on the market. Do manufacturers want to make something different for one state like California versus the rest of the country?" she said. "West Virginia is pretty small, so it's hard to know if this is really just going to mean certain foods just won't be sold in West Virginia, as opposed to separate products being developed for West Virginia."
Nationally, at least 30 color additives are
approved by the Federal Drug Administration
for use in food and drinks, including nine artificial dyes. Those nine require batch certification, meaning the FDA analyzes a sample from each batch of the additive to check if it meets certain requirements before it can be used.
The West Virginia ban is the most sweeping state level food dye regulation in the U.S. and includes:
Starting Aug. 1, these dies will not be in school meals in the state. Starting in January 2028, the dyes, along with preservatives butylated hydroxyanisole and propylparaben, will not be allowed in any foods, beverages or over-the-counter drugs sold in the state.
While you may not know these dyes by name, they can show up in your foods. Red No. 40, for example, can be found in salami, Yellow No. 6 in chicken bullion and Blue No. 1 in canned peas.
Gounder noted that states can follow what's known as the precautionary principle, "which is basically, 'better safe than sorry'" to ban food additives. The FDA, however, needs to go through a scientific process and show evidence of a risk first.
West Virginia Gov. Patrick Morrisey cited Health and Human Services Secretary
Robert F. Kennedy Jr.'s "Make American Healthy Again"
campaign in a statement released March 24 about the ban.
"West Virginia ranks at the bottom of many public health metrics, which is why there's no better place to lead the Make America Healthy Again mission," he said. "By eliminating harmful chemicals from our food, we're taking steps toward improving the health of our residents and protecting our children from significant long-term health and learning challenges."
Gounder also acknowledged Kennedy's influence.
"It's interesting because this is actually kind of importing European-style regulation to what is a very red, conservative state — so not what you would think of, but I think this is the influence of MAHA," she said. "Frankly, people on both sides of the aisle are really supportive of being healthier in this respect."
In 2023, California became the first state in the U.S. to issue a
ban
of Red No. 3 as well as potassium bromate, brominated vegetable oil and propylparaben. The ban starts in 2027.
California Gov. Gavin Newsom
also signed
legislation
, taking effect in 2028, that bans schools from serving or selling food and drinks with Blue No. 1, Blue No. 2, Green No. 3, Red No. 40, Yellow No. 5 and Yellow No. 6.
Several other states have introduced varying levels of bans or regulations on color additives, according to the
Environmental Working Group
, which advocates for changing industry health standards.
In January, the FDA announced its decision to
revoke the authorization
for one dye, Red No. 3, to be added to foods, after evidence showed a link between the dye and cancer in laboratory animals. Red 3, which is made of petroleum, is what gives a bright cherry-red color to a lot of foods and candies. It has already been banned in cosmetics and topical medications since 1990.
Companies are working to
update their products
to comply with the FDA's decision. They have until Jan. 15, 2027, to stop using the dye, the agency said.
Hundreds of food brands, including products ranging from candy and fruit cups to snack chips and tomato sauce, have contained Red 3 at some point, according to databases maintained by the
U.S. Department of Agriculture
and the nonprofit
Environmental Working Group
, as well as nutrition labels disclosed by food companies.
At the end of 2024, the FDA said it has not formally reevaluated the safety of
Red No. 40
, or Red 40 for short, in over a decade.
Jim Jones
, the former deputy commissioner for human foods, warned at the time their budget was too small.
An FDA study published
in 2016
estimated that children are exposed to Red 40 the most from drinks, frozen desserts and cereal.
Databases published by the
U.S. Department of Agriculture
and nonprofit
Environmental Working Group
tally thousands of foods with Red 40. Medications and cosmetics also have it.
In 2011, a panel of the FDA's food advisers voted against a warning like one that
authorities in Europe issued
for dyes, including Red 40, that says they "may have an adverse effect on activity and attention in children." Most of the advisers said at the time they thought studies fell short of proving causality.
The agency's science board concluded in 2019 that "most children have no effects from consuming foods containing color additives, though some evidence suggested that certain children may be part of a sensitive subpopulation," an FDA spokesperson said.
Gounder said there is "some evidence, at least for some kids" that these dyes can increase certain risks, including hyperactivity, sleeplessness and inattention.
"So especially for those kids where that impact has been seen, and taking those foods away relieves those symptoms, for those kids, especially, it is a good thing," she said.
Most calls to restrict Red 40 stem from research commissioned by British food authorities
in 2007
, which linked increases of hyperactivity in children to mixtures of synthetic dyes.
"If you talk to parents whose kids are sensitive to dyes, they'll tell you how difficult it is to avoid dyes and what a huge change it was for their entire household to try to get these dyes out of their kids' diets," environmental health consultant Lisa Lefferts
previously told CBS News.
For Red 3, the FDA has long said that it does not think evidence of it causing cancer applied to humans, but officials said their hand was forced by a law requiring the agency to pull additives that are cancerous in animals. A post on
the FDA's website
states, "claims that the use of FD&C Red No. 3 in food and in ingested drugs puts people at risk are not supported by the available scientific information."
If you want to limit dye intake, experts say to pay attention to labels.
"You can't look at the color. Even white foods may have synthetic dyes to make it brighter," Gounder previously said.
Alexander Tin
and
Emily Mae Czachor
contributed to this report.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Politico
40 minutes ago
- Politico
RFK Jr. guts ACIP. What happens next?
Presented by Driving the day ACIP FIRINGS ROCK WASHINGTON — HHS Secretary Robert F. Kennedy Jr. abruptly removed 17 vaccine experts from the CDC's Advisory Committee on Immunization Practices on Monday — and Washington is already reeling. 'The committee has been plagued with persistent conflicts of interest and has become little more than a rubber stamp for any vaccine,' Kennedy wrote in an opinion piece published in The Wall Street Journal. He wrote that the decision is meant to restore faith in vaccines. Public health experts and Democrats immediately condemned the action — which POLITICO reported was under consideration in February. 'This is absolutely unprecedented. RFK Jr. has many levers at his disposal to influence vaccine policy in the U.S., each with varying degrees of impact. But this move is a red-alert, level 4 alarm,' said Katelyn Jetelina, an epidemiologist who's consulted for the CDC. The biopharmaceutical industry also raised concerns. 'A wholesale change of this manner will negatively affect the Committee's ability to deliberate and make well-informed recommendations, putting American lives at risk,' Biotechnology Innovation Organization CEO John Crowley said in a statement. 'We agree that transparency is key to restoring trust in immunizations; however, the actions taken today upend a time-tested system that has protected American public health.' The removal of the experts also appears to buck the commitment Kennedy made to Senate Health, Education, Labor and Pensions Chair Bill Cassidy (R-La.) to 'maintain' the committee 'without changes.' But Cassidy told reporters at the U.S. Capitol that he spoke with Kennedy twice Monday and that the assurance he'd won from the now-secretary concerned ACIP's structure rather than membership. 'Of course, now the fear is that the ACIP will be filled up with people who know nothing about vaccines except suspicion,' Cassidy posted on X after the announcement. That fear was echoed by Democrats — who slammed the decision as a dangerous action that puts the health of Americans at risk. 'Secretary Kennedy is firing the 17 medical experts that advise our nation on immunization practices so he can stack the panel with a bunch of anti-vaccine wackos,' House Energy and Commerce ranking member Frank Pallone (D-N.J.) said in a statement. Remember: FDA Commissioner Marty Makary slammed ACIP as a 'kangaroo court' earlier this month on CBS' 'Face the Nation.' What's next: HHS said ACIP will still meet June 25-27, but with new membership. IT'S TUESDAY. WELCOME BACK TO PRESCRIPTION PULSE. Do you know how the decision to fire ACIP members went down? Send your tips to David Lim (dlim@ @davidalim or davidalim.49 on Signal) and Lauren Gardner (lgardner@ @Gardner_LM or gardnerlm.01 on Signal). Eye on the FDA DECISION TIME ON RSV — Two drug products targeting respiratory syncytial virus — a common bug that can cause severe illness in young babies and older adults — are on deck FDA decisions this week. Another antibody: The agency approved Merck's preventive monoclonal antibody Monday — a day ahead of schedule — for infants' first RSV season, injecting more competition into the RSV market. The company has designed the drug, dubbed Enflonsia, to be the same single dose administered to babies of any weight — a departure from Sanofi's Beyfortus, which is made in different dosage amounts depending on a baby or toddler's age and weight. Dr. Octavio Ramilo of St. Jude Children's Research Hospital, who worked as an investigator for Merck's trials for the drug, said its 'dosing convenience' and strong evidence showing reductions in disease and hospitalization make Enflonsia 'a promising new intervention to help protect infants from RSV.' Merck said it expects the CDC's external vaccine panel to make recommendations for the antibody's use at its next meeting in late June. The company statement came out just before HHS Secretary Robert F. Kennedy Jr.'s op-ed on the Advisory Committee on Immunization Practices was published. Another vaccine? Moderna is slated to get a decision on its mRNA vaccine for RSV in high-risk adults under 60 by Thursday. The FDA approved mResvia last year for adults 60 and older, and the company has said the shot met its study goals in the younger population. But Kennedy's suspicion of mRNA technology has prompted the federal government to pull funding from Moderna's bird flu vaccine program and to condition future Covid vaccine approvals for healthy people on more data, making the FDA's decision this week worth watching. Moderna stopped working on a version of the vaccine for children last year after receiving reports of severe lower respiratory tract infections in immunized trial participants. In Congress IN THE HOT SEAT — President Donald Trump's cuts to ideologically disfavored research have left the National Institutes of Health with unspent funds. Director Jay Bhattacharya, under pressure from critics on Capitol Hill and in the research community, is pledging to change that. But Democrats will get a chance to ask Bhattacharya for more details when he testifies before a Senate Appropriations subcommittee this morning. Pharma Moves Dr. Jennifer Peña is joining women's telehealth company Wisp as chief medical officer. She previously worked in similar roles at Oscar Health and Nurx and served as a White House physician under Barack Obama and Donald Trump. Document Drawer The FDA is publicizing a voluntary recall by Church & Dwight Co. of its Zicam nasal swabs and Orajel baby teething swabs due to potential fungi microbial contamination in the cotton swab components. No serious adverse events have been reported to date. The White House Office of Information and Regulatory Affairs is reviewing a 340B rebate guidance from the Health Resources and Services Administration. WHAT WE'RE READING STAT's Helen Branswell examines efforts by philanthropic leaders to maintain a network of labs that conduct surveillance of measles and rubella around the world following cuts by the Trump administration to global aid dollars. A bipartisan bill that tackles tools Medicare Advantage plans use to get higher payments from the federal government could be included in Senate Republicans' megabill, but a key Democrat doesn't want it in the package, POLITICO's Robert King and Meredith Lee Hill report. Nearly 50 food industry groups and companies are being invited by the White House to discuss a recent report on its Make America Healthy Again goals, POLITICO's Grace Yarrow reports.
Yahoo
40 minutes ago
- Yahoo
GT Medical Technologies Names James Leech Chief Financial and Strategy Officer
Experienced Life Sciences Executive Joins Leadership Team as Company Further Advances Commercialization of GammaTile® TEMPE, Ariz., June 10, 2025 /PRNewswire/ -- GT Medical Technologies, a medical device company with a corporate purpose of improving the lives of patients with brain tumors, today announced that James Leech, a seasoned financial and operational life sciences leader, has joined the company as Chief Financial and Strategy Officer. "We are excited to welcome James as he assumes the Chief Financial and Strategy Officer role at GT Medical Technologies," said Per Langoe, CEO of GT Medical Technologies. "I look forward to collaborating with him to ensure even more doctors and patients have access to GammaTile®. With over 10 years of successful experience leading commercial-stage healthcare-focused companies in an advisory and operational capacity, his expertise on a range of traditional and complex financial and strategic management areas provides us with a substantial opportunity for continued growth and adoption." Mr. Leech will work across the team to accelerate commercial opportunities for GammaTile while spearheading corporate strategy and development, as well as financial and investor management. "I look forward to joining a leadership team that is dedicated to transforming the lives of patients with brain tumors," said Mr. Leech. "GT Medical Technologies is poised for significant growth, and I am thrilled to collaborate with all stakeholders to optimize the company's continued expansion of GammaTile, our FDA-cleared bioresorbable radiotherapy implant for the treatment of brain tumors." Mr. Leech has considerable experience leading businesses from inception through hyper growth phases of their life cycle. He has advised and worked across the life science industry with direct experience in MedTech, healthcare services, and biopharmaceutical sectors across all major therapeutic areas. Previously, Mr. Leech was the Chief Financial and Strategy Officer of Moximed, a commercial-stage orthopedic device company. Prior to Moximed, Mr. Leech was the Chief Business Officer at Palette Life Sciences from the Company's inception through its acquisition by Teleflex, Inc. Mr. Leech started his career in life science investment banking and strategy consulting. He brings significant cross-border experience, having executed transactions and operational initiatives on behalf of and involving companies across the EU and APAC. GammaTile is an innovative form of radiation therapy placed at the time of tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are most vulnerable. Unlike conventional approaches, which at their lowest often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment's effectiveness against remaining cancer cells and reduce the risk of regrowth.1 About GT Medical Technologies, Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care. About GammaTileGammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. By delivering radiation directly from within—placed into the surgical cavity at the time of tumor removal—GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are most vulnerable to help prevent regrowth, while minimizing radiation exposure to healthy brain tissue. Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit and follow @GammaTile on Facebook, Instagram, LinkedIn and X. Media ContactDawn FallonNew Dawn Communications LLCDfallon@ References Garcia MA et al. J Neurooncol. 166:203-212 (2024). View original content to download multimedia: SOURCE GT Medical Technologies
Yahoo
40 minutes ago
- Yahoo
NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China
LOS ANGELES, June 10, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating attention-deficit hyperactivity disorder (ADHD), today announced a notice of allowance in China for a patent protecting the Monarch eTNS System. The patent, titled Pulse Generator for Trigeminal Nerve Stimulation, protects certain embodiments of NeuroSigma's core eTNS technology, including its second-generation Monarch device. The patent was allowed by China's National Intellectual Property Administration on May 27, 2025. In 2022, NeuroSigma licensed rights to the Monarch eTNS System for treating ADHD in China to Ignis Therapeutics, a leader in the development of novel therapeutics for central nervous system (CNS) conditions. 'As NeuroSigma continues to grow and work with our partners at Ignis, China will be a critical market for the Monarch eTNS System,' said Colin Kealey, M.D., President and CEO of NeuroSigma. 'This patent protects our second-generation Monarch device in China and significantly strengthens the company's intellectual property position.' "NeuroSigma's Monarch eTNS System is a highly innovative and effective therapy for ADHD,' added Tom Paschall, Director of NeuroSigma and CEO of Checkmate Capital. 'China is one of the largest and most important markets in the world for new CNS therapies. With this patent award, the Monarch device will benefit from robust intellectual property protection, which, we believe, will facilitate commercialization in this key market.' About NeuroSigma NeuroSigma is a Los Angeles, California-based bioelectronic medical device company developing technologies to transform medical practice and patients' lives. The company's lead product is the Monarch eTNS System, which is the first non-drug treatment for pediatric ADHD cleared by the FDA. Pipeline indications for the Monarch eTNS System include neurodevelopmental disorders such as autism spectrum disorder (ASD), learning disabilities, and epilepsy. NeuroSigma has received Breakthrough Device Designation for the Monarch eTNS System from the FDA in drug-resistant epilepsy. For more information about NeuroSigma, please visit For more information on the Monarch eTNS System, please visit Contact:Colin Kealey, M.D., President of NeuroSigma at CKealey@